bpc-157 research human safety and the Difference Between an Evidence Gap and a Cover-Up: What the entire evidence base actually looks like, and the questions to ask next. — WellFounded BPC-157 – The Stable Gastric Pentadecapeptide BPC

After cessation of cuprizone treatment after acute and chronic demyelination astrogliosis is persisting over a period of weeks during the remyelination period, which is in contrast to the transient activation of microglia (Skripuletz et al., 2011a

Mechanism of Action BPC-157 does not bind to a single well-characterised receptor in the way that, for example, GLP-1 receptor agonists or ghrelin secretagogues do

Strand Therapeutics Series B $153M August 2025 Strand Therapeutics, a leader in programmable mRNA therapies, raised $153 million in series B funding led by Kinnevik, with participation from Regeneron Ventures, ICONIQ, Amgen Ventures, Alderline Group, JIC-VGI, LG Technology Ventures, Gradiant Corporation, and existing investors, bringing total funding to over $250 million

Compared to other peptides for fat loss The peptide landscape for fat loss includes several options beyond GLP-1 agonists